Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Adempas riociguat regulatory update

In a pair of 11-0 votes, FDA's Cardiovascular and Renal Drugs Advisory Committee recommended approval of Adempas

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE